Iqirvo PBC denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Iqirvo (elafibranor) for Primary Biliary Cholangitis as Duplicate Therapy

Aetna's duplicate-therapy edit for Iqirvo in primary biliary cholangitis (PBC) is triggered when the claim system detects that another PBC-targeted therapy — most commonly ursodiol (UDCA) or obeticholic acid — is already on file for the same member. Aetna's coverage logic reflects clinical guidelines that specify the sequence in which PBC therapies are initiated and combined: UDCA is typically first-line, and second-line agents like Iqirvo are added or substituted when UDCA response is inadequate. The duplicate flag fires when the system interprets a combination or transition as an unsupported concurrent regimen.

This denial is frequently generated in error. UDCA and Iqirvo may be intended as an appropriate combination per the FDA label and the applicable guideline organization; or the patient may be transitioning off a prior second-line agent while Iqirvo is being initiated, leaving a brief overlap in the claims record. Neither scenario reflects clinically inappropriate prescribing.

## Why This Denial Is Appealable

The duplicate-therapy denial is administrative, not a clinical finding. When the prescriber documents that the combination is intentional, on-label, and supported by the clinical situation, the denial has no substantive basis. Aetna's own coverage policies for PBC agents acknowledge combination therapy in certain clinical contexts.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on your Explanation of Benefits. Aetna must decide within 30 days (non-urgent) or 72 hours (expedited).
• External review (ACA §2719): After an adverse internal decision, an independent review organization evaluates whether the duplicate-therapy determination is clinically supported. The window is generally up to four months from the denial notice.
• ERISA §503: Employer-plan members have federal full-and-fair review rights including access to all documents Aetna relied on.
• Expedited review: Request if your prescriber certifies that delay would seriously jeopardize your health given the progressive nature of PBC.

## Documentation to Gather

1. Diagnosis confirmation — Gastroenterologist or hepatologist records with a confirmed PBC diagnosis, including relevant laboratory and imaging findings. 2. Current medication list — A signed, dated reconciliation confirming what is currently being taken, with start and stop dates for any prior PBC agent. 3. Combination or transition rationale — Prescriber letter explaining whether UDCA is being continued alongside Iqirvo (and the clinical basis for that combination) or whether a prior second-line agent was discontinued before Iqirvo was initiated. 4. Prior-treatment history — Dates and outcomes of UDCA therapy and any other prior PBC agents, establishing the clinical context for adding or switching to Iqirvo. 5. Prescriber medical-necessity letter — Confirms the treatment plan, explains the role of each current medication, and references alignment with the applicable professional guideline organization (e.g., AASLD, EASL).

## Criteria-Mapping Structure

Obtain Aetna's published coverage policy for PBC agents. For each stated criterion:

• Confirmed PBC diagnosis by a qualified specialist — hepatologist or gastroenterologist records
• Prior UDCA trial with documented response assessment (reference the prescribing label and applicable guideline organization for response criteria, not specific numeric cutoffs)
• Clinical rationale for combination or for transition to Iqirvo — prescriber letter
• No unsupported duplication of mechanism — prescriber letter clarifying the role of each agent

A focused prescriber letter that explicitly addresses the duplicate flag — explaining the combination rationale or the transition timeline — is the critical piece that turns this denial around.